How We Aim To Help Patients

We aim to accelerate the clinical translation of pluripotent stem cell production and specialization so that our partners can bring regenerative cell treatment to patients worldwide, with an initial focus on Africa. Our goal is to commercialize a safe and comprehensive tissue regeneration treatment for victims of immunodeficiency diseases, like blood cancers and HIV, as soon as possible.

How We Hope to Help Health Workers, Hospitals, Institutions and Medical Facilities

Neurosurgeons, physicians, physiotherapists and other healthcare workers need not be reminded how devastating for a patient a severe spinal cord injury is, nor what conviction is required in the long-term caring for a quadriplegic patient. Our ability to produce autoregenic cells opens up an experimental treatment for C1-5 quadriplegia using ethically produced (via iSCNT), patient-specific pre-neural stem cells with which to re-originate sections of cauterized spinal cords. With the support of researchers and clinical collaborators, we will soon be able to offer training in the application of autoregenic cells to neurosurgeons and specialist clinicians so they may offer their quadriplegic patients an experimental spinal cord regeneration procedure. Regulations permitting, we are eager to partner with the world’s most skilled and progressive neurosurgeons to accelerate the clinical translation of this innovation.

How We Aim to Help

Health Workers, Hospitals, Institutions and Medical Facilities

Oncologists and other healthcare workers need not be reminded how devastating for a patient a progressive immunodeficiency disease is. Our ability to produce infusions of hematopoietic stem and progenitor cells (HSPCs) opens up an experimental treatment for late-stage blood cancer patients using ethically produced, patient-specific biologics with which to re-populate exhausted immune systems. With the support of researchers and clinical collaborators, we plan to offer training in the application of HSPCs to oncologists and specialist clinicians so they may offer their patients an experimental recovery treatment. Regulations permitting, we seek to partner with the world’s most skilled and progressive oncologists to accelerate the clinical translation of this innovation.

How We Aim To Help         Stem Cell Donor Networks

Our stem cell manufacturing methodology utilizes either small skin biopsies or mesenchymal stem cells as the vehicle for donation of essential DNA. While current blood donation methods struggle with the logistics of recruiting and harvesting blood from patient-matched donors, our process requires only a single donation of a biopsy to result in a permanent, self-renewing sample of naive pluripotent stem cells. From these pluripotent stem cells, we can rapidly produce practically unlimited supplies of re-birthed stem cells for any number of patients. We seek to work with progressive partners to accelerate the clinical translation of our innovation for the betterment of humankind.